PRO 140 for Human Immunodeficiency Virus Infection
Withdrawn before enrolling · Phase 2
Conditions studied: HIV
In brief
PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.
Key facts
- Study ID
- NCT02257788
- Run by
- Drexel University
- People needed
- 0
- Starts
- 2014-09-01
- Expected to finish
- 2015-02-01
- Last updated by the study team
- 2017-03-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Males and females, age ≥18 years
- Has not taken any antiretroviral therapy (ART) within 12 weeks of the early screening visit
- Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
- CD4+ lymphocyte cell count ≥500 cells/mm3 and no documented count less than or equal to 250 cells/mm3
- Exclusive CCR5-tropic virus as determined by as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay
- Clinically normal resting 12-lead ECG at screening visit
- Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit. Within hours prior to receiving the first dose of study drug, women of reproductive potential must have a negative urine pregnancy test. Male and female subjects must agree not to participate in a conception process and agree to use one barrier method of contraception plus one other highly reliable contraceptive method from the early screening visit through three weeks after the last administered subcutaneous dose of PRO 140.
You may not qualify if…
- CXCR4-tropic virus, dual/mixed tropic (R5X4) virus as determined by the Enhanced Sensitivity Trofile™ HIV Tropism Assay
- Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
- Diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within 24 weeks of dosing)
- Chronic hepatitis
- Prior use of any entry, attachment, CCR5 coreceptor, or fusion inhibitor, including PRO 140, experimental or approved
- Any immunization or vaccination (including influenza vaccine) within 30 days prior to administration of study drug.
Where it is running
- Stanford University (Stanford AIDS Clinical Trials Unit) — Stanford, California, United States
- University of Colorado Denver (Colorado ACTU) — Denver, Colorado, United States
- Washington University in St. Louis — St Louis, Missouri, United States
- University of Rochester Medical Center — Rochester, New York, United States
- Drexel University College of Medicine — Philadelphia, Pennsylvania, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- University of Texas Health Science Center at Houston (Houston AIDS Research team (HART) — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.